TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Zhaoke Ophthalmology Ltd. ( (HK:6622) ) has issued an announcement.
Zhaoke Ophthalmology Limited has announced a distribution agreement with AFT Pharmaceuticals to commercialize BRIMOCHOL PF in Australia and New Zealand. BRIMOCHOL PF is an eye drop aimed at treating presbyopia, a common age-related vision problem, and has shown promising Phase 3 trial results. This agreement allows AFT exclusive rights to market and distribute the product, potentially enhancing Zhaoke’s market presence in the Asia-Pacific region and offering a novel therapeutic option where few exist.
More about Zhaoke Ophthalmology Ltd.
Zhaoke Ophthalmology Limited is a company focused on developing innovative ophthalmic treatments, particularly in the eye care industry. They are collaborating with global biotech companies like Tenpoint Therapeutics to create groundbreaking solutions for vision issues related to aging.
YTD Price Performance: 9.17%
Average Trading Volume: 682,636
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$715.4M
For detailed information about 6622 stock, go to TipRanks’ Stock Analysis page.